Literature DB >> 28298667

Suspected Heparin-Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation.

Bhupinder Natt1, Cameron Hypes2, Robyn Basken3, Joshua Malo1, Toshinobu Kazui4, Jarrod Mosier2.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune reaction usually secondary to unfractionated heparin. Anticoagulation management is critical in patients while on extracorporeal membrane oxygenation (ECMO) to prevent thromboembolism and for the optimal functioning of the circuit. We identified five patients with respiratory failure at our hospital managed with ECMO in the last 2 years that were treated for HIT. A brief clinical course and their management are discussed. We also briefly review the literature for best evidence for management of such patients.

Entities:  

Keywords:  ECMO; HIT; antibody; anticoagulation

Mesh:

Substances:

Year:  2017        PMID: 28298667      PMCID: PMC5347221     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  18 in total

1.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.

Authors:  G K Lo; D Juhl; T E Warkentin; C S Sigouin; P Eichler; A Greinacher
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.

Authors:  Joseph Schwartz; Anand Padmanabhan; Nicole Aqui; Rasheed A Balogun; Laura Connelly-Smith; Meghan Delaney; Nancy M Dunbar; Volker Witt; Yanyun Wu; Beth H Shaz
Journal:  J Clin Apher       Date:  2016-06       Impact factor: 2.821

Review 4.  Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis.

Authors:  Andreas Greinacher; Theodore E Warkentin
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

5.  Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass.

Authors:  A Lillo-Le Louët; P Boutouyrie; M Alhenc-Gelas; C Le Beller; I Gautier; M Aiach; D Lasne
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

6.  Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study.

Authors:  Matthew Kang; Majed Alahmadi; Sonja Sawh; Michael J Kovacs; Alejandro Lazo-Langner
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

7.  Platelet Count Trends and Prevalence of Heparin-Induced Thrombocytopenia in a Cohort of Extracorporeal Membrane Oxygenator Patients.

Authors:  Mladen Sokolovic; Alexandra K Pratt; Vladimir Vukicevic; Molly Sarumi; Laura S Johnson; Nimesh S Shah
Journal:  Crit Care Med       Date:  2016-11       Impact factor: 7.598

8.  Association of thrombocytopenia with the use of intra-aortic balloon pumps.

Authors:  R H Vonderheide; R Thadhani; D J Kuter
Journal:  Am J Med       Date:  1998-07       Impact factor: 4.965

Review 9.  How we manage patients with heparin induced thrombocytopenia.

Authors:  Marie Scully; Carolyn Gates; Lucy Neave
Journal:  Br J Haematol       Date:  2016-04-21       Impact factor: 6.998

10.  Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated.

Authors:  F Pappalardo; G Maj; A Scandroglio; F Sampietro; A Zangrillo; A Koster
Journal:  Perfusion       Date:  2009-03       Impact factor: 1.972

View more
  5 in total

Review 1.  Physiology of the Assisted Circulation in Cardiogenic Shock: A State-of-the-Art Perspective.

Authors:  Julien Guihaire; Francois Haddad; Mita Hoppenfeld; Myriam Amsallem; Jeffrey W Christle; Clark Owyang; Khizer Shaikh; Joe L Hsu
Journal:  Can J Cardiol       Date:  2019-11-09       Impact factor: 5.223

2.  Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review.

Authors:  Han Zhong; Ming-Li Zhu; Yue-Tian Yu; Wen Li; Shun-Peng Xing; Xian-Yuan Zhao; Wei-Jun Wang; Zhi-Chun Gu; Yuan Gao
Journal:  Front Pharmacol       Date:  2020-09-11       Impact factor: 5.810

Review 3.  Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes.

Authors:  Jae Hwan Choi; Jessica G Y Luc; Matthew P Weber; Haritha G Reddy; Elizabeth J Maynes; Avijit K Deb; Louis E Samuels; Rohinton J Morris; H Todd Massey; Antonio Loforte; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2019-01

Review 4.  Complications of Temporary Percutaneous Mechanical Circulatory Support for Cardiogenic Shock: An Appraisal of Contemporary Literature.

Authors:  Anna V Subramaniam; Gregory W Barsness; Saarwaani Vallabhajosyula; Saraschandra Vallabhajosyula
Journal:  Cardiol Ther       Date:  2019-10-23

5.  Suspected heparin-induced thrombocytopenia in a COVID-19 patient on extracorporeal membrane oxygenation support: a case report.

Authors:  Xuan T Phan; Tuan H Nguyen; Tung T Tran; Thu-Hien T Huynh; Thuy-Ha T Hoang; Vinh-Chau V Nguyen; Thao N T Pham
Journal:  Thromb J       Date:  2020-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.